Real-world study of use patterns and clinical outcomes for patients with myelodysplastic syndrome initiating oral decitabine and cedazuridine or intravenous/subcutaneous hypomethylating agents.

Ther Adv Hematol · 2026 · PMC12921205 · PMID 41725789

Europe PMC DOI

hedged sentence

0.1000

closest p · 2.0× alpha

0.1000

boldest claim

The sentences

did not reach statistical significancep = 0.10so close (0.05 < p ≤ 0.1)

In the AML-free survival analysis, 236 of the 399 IV/SC HMA patients and 205 of the 399 DEC-C patients progressed to AML or died; here the AML-free survival was still numerically longer among DEC-C patients compared to IV/SC HMA patients (median 16.1 months vs 14.3 months, respectively), but this difference did not reach statistical significance ( p = 0.10; Figure 2(b) ).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.